Bilateral Nasal Polyposis
4
0
0
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
3 treatments under study, led by Fluticasone Propionate
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 4 trials
100.0%
+13.4% vs benchmark
75%
3 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (4)
OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps
A Study to Evaluate the Effect of ACT-774312 in Subjects With Bilateral Nasal Polyposis
Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety
Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device
Research Network
Common Treatments
- Fluticasone Propionate2
- Opn3751
- Act7743121
Active Sponsors
- Optinose US Inc.3
- Paratek Pharmaceuticals Inc1
- Idorsia Pharmaceuticals Ltd.1
Top Investigators
Paratek Pharma